Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-11T22:57:53.678Z Has data issue: false hasContentIssue false
  • English
  • Français

The Challenge of Nanomedicine Human Subjects Research: Protecting Participants, Workers, Bystanders, and the Environment

Published online by Cambridge University Press:  01 January 2021

Susan M. Wolf
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Introduction
Information
Journal of Law, Medicine & Ethics , Volume 40 , Issue 4 , Winter 2012 , pp. 712 - 715
Copyright
Copyright © American Society of Law, Medicine and Ethics 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

45 C.F.R. part 46 (2011).Google Scholar
21 C.F.R. parts 50, 56 (2012).Google Scholar
See Wolf, S. M. and Jones, C. M., “Designing Oversight for Nanomedicine Research in Human Subjects: Systematic Analysis of Exceptional Oversight for Emerging Technologies,” Journal of Nanoparticle Research 13, no. 4 (2011): 1449–1465.CrossRefGoogle Scholar
See NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines), March 2013, available at <http://oba.od.nih.gov/oba/rac/Guidelines/NIH_Guidelines_new.pdf> (last visited October 15, 2012), amending NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) (October 2011), available at <http://oba.od.nih.gov/oba/rac/Guidelines/NIH_Guidelines.pdf> (last visited October 15, 2012).+(last+visited+October+15,+2012),+amending+NIH+Guidelines+for+Research+Involving+Recombinant+DNA+Molecules+(NIH+Guidelines)+(October+2011),+available+at++(last+visited+October+15,+2012).>Google Scholar
See id.Google Scholar
Etheridge, M. L. Campbell, S. A., and Erdman, A. G. et al., “The Big Picture on Nanomedicine: The State of Investigational and Approved Nanomedicine Products,” Nanomedicine: Nanotechnology, Biology, and Medicine (forthcoming 2013).CrossRefGoogle Scholar
See Fleege, L. and Lawrenz, F., “An Empirical Examination of the Current State of Publically Available Nanotechnology Guidance Materials,” Journal of Law, Medicine & Ethics 40, no. 4 (2012): 751–762.CrossRefGoogle Scholar
See Consortium on Law and Values, available at <http://www.lifesci.consortium.umn.edu/newsevents/conferences/nanodiagnanother/home.html> (last visited October 15, 2012).+(last+visited+October+15,+2012).>Google Scholar
Fatehi, L. Wolf, S. M., and McCullough, J. et al., “Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field,” Journal of Law, Medicine & Ethics 40, no. 4 (2012): 751–750.CrossRefGoogle Scholar
See, e.g., Mandel, G. N., “Regulating Emerging Technologies,” Law, Innovation & Technology 1, no. 1 (2009): 75–92; Marchant, G. E. Sylvester, D. J., and Abbott, K. W., “What Does the History of Technology Regulation Teach Us about Nano Oversight?” Journal of Law, Medicine & Ethics 37, no. 4 (2009): 724–731.CrossRefGoogle Scholar
National Nanotechnology Initiative (NNI), NNI Budget, available at <http://www.nano.gov/about-nni/what/funding> (last visited September 18, 2012).+(last+visited+September+18,+2012).>Google Scholar
See, e.g., Wagner, V. Dullaart, A., and Bock, A.-K. et al., “The Emerging Nanomedicine Landscape,” Nature Biotechnology 24, no. 10 (2006): 1211–1217.CrossRefGoogle Scholar